Opinion

Podcast

Empowering Patients: Navigating the Progression Risks of Actinic Keratosis and Optimizing Treatment Selection

In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.

To watch the video series component of this episode, click here.

00:00 Introduction

00:55 Educating your patients with actinic keratosis on progression to squamous cell carcinoma and field cancerization.

06:15 The different treatments options available for actinic keratosis.

07:42 Evidence based treatment selection in actinic keratosis; sequencing and combining therapies

10:48 Photodynamictherapy for treatment of actinic keratosis

14:38 Comparing blue versus red light

20:30 Comparison studies on photodynamic therapy used with various used in combination with formulations of photosensitizing agent

24:10 Optimizing the use of photodynamic therapy for extremities in patients with actinic keratosis

27:50 The efficacy, safety and adherence of the different treatment modalities based in actinic keratosis

31:45 Summary

Related Videos
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Atypical Clinical Presentations of Blistering Disease, with Donna Culton, MD, PhD
How to Address Blistering Diseases, with Donna Culton, MD, PhD
Differentiating Between Different Types of Alopecia, with Jerry Shapiro, MD
Julie Harper, MD: Discussing Acne Treatment Updates, Unmet Needs Among Patients
Review of Recent Advancements in Dermatology, with Matthew Zirwas, MD
Raj Chovatiya, MD, PhD: Treating Hidradenitis Suppurativa with IL-17, JAK Inhibitors
© 2024 MJH Life Sciences

All rights reserved.